Recommended COVID-19 vaccines for people who ARE moderately or severely immunocompromised, aged 6 months–4 years, mRNA vaccines, with vial icons and dosages, May 2023*

*For product- and vaccination history-specific dosages, administration intervals, and additional dose information, see Table 2 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

**Key**
- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech

---

Centers for Disease Control and Prevention | Recommended COVID-19 vaccines, May 2023 | Page 1
Recommended COVID-19 vaccines for **people who ARE moderately or severely immunocompromised, aged 5 years**, mRNA vaccines, *with vial icons and dosages*, May 2023*

<table>
<thead>
<tr>
<th>COVID-19 vaccination status May 2023</th>
<th>Unvaccinated</th>
<th>Vaccinated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previously received vaccine(s)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Number of doses indicated, by manufacturer</th>
<th>Moderna</th>
<th>Pfizer-BioNTech</th>
<th>Moderna OR Pfizer-BioNTech</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 doses</td>
<td>Moderna</td>
<td>0.25 mL/25 ug</td>
<td>Moderna OR Pfizer-BioNTech</td>
</tr>
<tr>
<td>3 doses</td>
<td>Pfizer-BioNTech</td>
<td>0.2 mL/10 ug</td>
<td></td>
</tr>
<tr>
<td>2 doses</td>
<td>Moderna</td>
<td>0.25 mL/25 ug</td>
<td>Moderna OR Pfizer-BioNTech</td>
</tr>
<tr>
<td>1 dose</td>
<td>Moderna</td>
<td>0.25 mL/25 ug</td>
<td>Moderna OR Pfizer-BioNTech</td>
</tr>
<tr>
<td>3 doses</td>
<td>Moderna</td>
<td>0.25 mL/25 ug</td>
<td>Moderna OR Pfizer-BioNTech</td>
</tr>
<tr>
<td>3 doses</td>
<td>Moderna</td>
<td>0.2 mL/10 ug</td>
<td>Moderna OR Pfizer-BioNTech</td>
</tr>
<tr>
<td>1 dose</td>
<td>Moderna</td>
<td>0.25 mL/25 ug</td>
<td>Moderna OR Pfizer-BioNTech</td>
</tr>
<tr>
<td>2 doses</td>
<td>Moderna</td>
<td>0.25 mL/25 ug</td>
<td>Moderna OR Pfizer-BioNTech</td>
</tr>
<tr>
<td>1 dose</td>
<td>Moderna</td>
<td>0.25 mL/25 ug</td>
<td>Moderna OR Pfizer-BioNTech</td>
</tr>
<tr>
<td>1 dose</td>
<td>Pfizer-BioNTech</td>
<td>0.2 mL/10 ug</td>
<td>Moderna OR Pfizer-BioNTech</td>
</tr>
<tr>
<td>1 dose</td>
<td>Pfizer-BioNTech</td>
<td>0.2 mL/10 ug</td>
<td>Moderna OR Pfizer-BioNTech</td>
</tr>
</tbody>
</table>

**ADDITIONAL BIVALENT mRNA DOES ARE AUTHORIZED***

*For administration intervals, additional dose information, and options for heterologous dosing, see Table 2 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

**Key**

- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech

---

05/16/23
Recommended COVID-19 vaccines for **people who ARE moderately or severely immunocompromised, aged 6–11 years**, mRNA vaccines, with vial icons and dosages, May 2023*

For product-specific dosages, administration intervals, additional dose information, and options for heterologous dosing, see Table 2 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

**Key**

- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech

*For product-specific dosages, administration intervals, additional dose information, and options for heterologous dosing, see Table 2 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.
Recommended COVID-19 vaccines for **people who ARE moderately or severely immunocompromised, aged 12 years and older, mRNA vaccines, with vial icons and dosages, May 2023***

*For administration intervals, additional dose information, and options for heterologous dosing, see Table 2 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

**Key**
- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech

---

**COVID-19 vaccination status May 2023**

- **Unvaccinated**
- **Vaccinated**

**Previously received vaccine(s)**

**Number of doses indicated, by manufacturer**

**ADDITIONAL BIVALENT mRNA DOSES ARE AUTHORIZED***
Recommended COVID-19 vaccines for people who ARE moderately or severely immunocompromised, aged 6 months–4 years, mRNA vaccines, May 2023*

*For product- and vaccination history-specific dosages, administration intervals, and additional dose information, see Table 2 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

Key
- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech
Recommended COVID-19 vaccines for **people who ARE moderately or severely immunocompromised, aged 5 years**, mRNA vaccines, May 2023*

<table>
<thead>
<tr>
<th>Previously received vaccine(s)</th>
<th>Vaccinated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unvaccinated</td>
<td></td>
</tr>
</tbody>
</table>

**COVID-19 vaccination status May 2023**

<table>
<thead>
<tr>
<th>Number of doses indicated, by manufacturer</th>
<th>Vaccinated</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 doses bivalent Moderna</td>
<td>1 dose bivalent Moderna</td>
</tr>
<tr>
<td>2 doses bivalent Moderna</td>
<td>2 doses bivalent Moderna</td>
</tr>
<tr>
<td>1 dose bivalent Moderna</td>
<td>3 doses bivalent Moderna and 1 dose bivalent mRNA</td>
</tr>
<tr>
<td></td>
<td>3 doses bivalent Moderna and 1 dose bivalent mRNA</td>
</tr>
<tr>
<td></td>
<td>3 doses bivalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTech</td>
</tr>
</tbody>
</table>

**ADDITIONAL BIVALENT mRNA DOSES ARE AUTHORIZED**

*For product- and vaccination-history-specific dosages, administration intervals, additional dose information, and options for heterologous dosing, see Table 2 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

**Key**

- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech

---

---

---
Recommended COVID-19 vaccines for people who ARE moderately or severely immunocompromised, aged 6 years and older, mRNA vaccines, May 2023*

*For product-specific dosages, administration intervals, additional dose information, and options for heterologous dosing, see Table 2 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

Key
- Moderna
- Pfizer-BioNTech
- Moderna OR Pfizer-BioNTech

ADDITIONAL BIVALENT mRNA DOES ARE AUTHORIZED*